NASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PMVP Stock Alerts $1.80 +0.07 (+4.03%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.71▼$1.8550-Day Range$1.51▼$1.9352-Week Range$1.18▼$9.72Volume371,068 shsAverage Volume513,794 shsMarket Capitalization$92.85 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PMV Pharmaceuticals alerts: Email Address PMV Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside213.9% Upside$5.67 Price TargetShort InterestBearish6.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.44) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 starsMedical Sector582nd out of 909 stocksPharmaceutical Preparations Industry262nd out of 425 stocks 3.5 Analyst's Opinion Consensus RatingPMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePMV Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.40% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in PMV Pharmaceuticals has recently increased by 15.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMVP. Previous Next 3.2 News and Social Media Coverage News SentimentPMV Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for PMVP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of PMV Pharmaceuticals is held by insiders.Percentage Held by Institutions90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.44) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About PMV Pharmaceuticals Stock (NASDAQ:PMVP)PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Read More PMVP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMVP Stock News HeadlinesApril 19, 2024 | finance.yahoo.comPMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth PlansApril 18, 2024 | msn.comPMV Pharmaceuticals (PMVP) Price Target Increased by 45.83% to 8.93April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 14, 2024 | americanbankingnews.comPMV Pharmaceuticals (NASDAQ:PMVP) Now Covered by Jefferies Financial GroupMarch 27, 2024 | globenewswire.comPMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsMarch 18, 2024 | finance.yahoo.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerMarch 18, 2024 | globenewswire.comPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's CancerMarch 16, 2024 | finance.yahoo.comPMVP Apr 2024 5.000 callApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 3, 2024 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsMarch 1, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)March 1, 2024 | finance.yahoo.comPMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)February 29, 2024 | globenewswire.comPMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsFebruary 26, 2024 | finance.yahoo.comPMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceJanuary 19, 2024 | finanznachrichten.dePMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayJanuary 18, 2024 | marketwatch.comPMV Phamra to Prioritize PC14586 Clinical Development, Will Cut Staff by 30%January 18, 2024 | msn.comPMV to focus on lead drug, slashes workforce by 30%January 18, 2024 | finance.yahoo.comPMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayJanuary 5, 2024 | msn.comPMV Pharmaceuticals names Michael Carulli as CFOJanuary 5, 2024 | finance.yahoo.comPMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentDecember 28, 2023 | msn.comLadenburg Thalmann starts PMV Pharmaceuticals at buyDecember 28, 2023 | benzinga.comPMV Pharma Stock (NASDAQ:PMVP), Analyst Ratings, Price Targets, PredictionsDecember 27, 2023 | benzinga.comPMV Pharma Stock (NASDAQ:PMVP), Short Interest ReportDecember 27, 2023 | msn.comLadenburg Thalmann Initiates Coverage of PMV Pharmaceuticals (PMVP) with Buy RecommendationDecember 27, 2023 | msn.com2 Red-Hot Stocks Highlight Wednesday's Top Wall Street Upgrades and DowngradesDecember 27, 2023 | finance.yahoo.comGracell downgrade, Fusion upgrade: Wall Street's top analyst callsSee More Headlines Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PMVP CUSIPN/A CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees63Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+213.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.27% Return on Assets-27.33% Debt Debt-to-Equity RatioN/A Current Ratio14.78 Quick Ratio14.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.41Miscellaneous Outstanding Shares51,440,000Free Float47,533,000Market Cap$92.85 million OptionableOptionable Beta1.65 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. David H. Mack Ph.D. (Age 62)Co-Founder, CEO, President & Director Comp: $762.02kDr. Arnold J. Levine Ph.D. (Age 84)Co-Founder, Director & Member of Scientific Advisory Board Comp: $140kDr. Thomas E. Shenk Ph.D. (Age 77)Co-Founder & Member of Scientific Advisory Board Mr. Michael CarulliChief Financial OfficerMr. Robert Ticktin (Age 62)General Counsel, Head of Operations & Company Secretary Mr. Tim SmithSenior VP & Head of Corporate Development and Investor RelationsMs. Crystal ZuckermanVice President of Human ResourcesDr. Binh Vu Ph.D.Senior VP of Drug Discovery & CMCDr. Deepika Jalota Pharm.D. (Age 47)Chief Development Officer Comp: $579.96kDr. Marc Fellous M.D.Senior VP and Head of Clinical Development & Medical AffairsMore ExecutivesKey CompetitorsProPhase LabsNASDAQ:PRPHAbeona TherapeuticsNASDAQ:ABEOAllakosNASDAQ:ALLKGeneluxNASDAQ:GNLXDiaMedica TherapeuticsNASDAQ:DMACView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 1,306,490 shares on 4/23/2024Ownership: 2.540%Fishman Jay A Ltd. MIBought 50,000 shares on 4/23/2024Ownership: 0.156%PFM Health Sciences LPBought 177,909 shares on 2/15/2024Ownership: 2.879%Sectoral Asset Management Inc.Bought 382,161 shares on 2/14/2024Ownership: 1.341%Personal CFO Solutions LLCBought 200,000 shares on 2/14/2024Ownership: 1.076%View All Insider TransactionsView All Institutional Transactions PMVP Stock Analysis - Frequently Asked Questions Should I buy or sell PMV Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMVP shares. View PMVP analyst ratings or view top-rated stocks. What is PMV Pharmaceuticals' stock price target for 2024? 3 brokers have issued 1-year price targets for PMV Pharmaceuticals' shares. Their PMVP share price targets range from $5.00 to $7.00. On average, they expect the company's share price to reach $5.67 in the next year. This suggests a possible upside of 213.9% from the stock's current price. View analysts price targets for PMVP or view top-rated stocks among Wall Street analysts. How have PMVP shares performed in 2024? PMV Pharmaceuticals' stock was trading at $3.10 at the beginning of the year. Since then, PMVP shares have decreased by 41.8% and is now trading at $1.8050. View the best growth stocks for 2024 here. When is PMV Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PMVP earnings forecast. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.08. What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE). When did PMV Pharmaceuticals IPO? PMV Pharmaceuticals (PMVP) raised $126 million in an IPO on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO. Who are PMV Pharmaceuticals' major shareholders? PMV Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (2.54%) and Fishman Jay A Ltd. MI (0.16%). Insiders that own company stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Deepika Jalota, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Orbimed Advisors Llc, Paul Klauder, Richard A Heyman, Thilo Schroeder and Winston Kung. View institutional ownership trends. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMVP) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
